Used as a potent and selective inhibitor in targeted cancer therapies, particularly in the treatment of certain leukemias. It functions by blocking the activity of specific tyrosine kinases involved in tumor growth and proliferation. Its structure allows for high binding affinity to mutated forms of kinase enzymes, making it effective against resistant cancer strains. Commonly employed in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with BCR-ABL1 mutations. Shows improved central nervous system penetration, beneficial for managing central nervous system involvement in leukemia. Also under investigation for use in solid tumors with specific genetic alterations.